Background: Ovarian cancer remains the most common lethal gynecologic malignancy. The
therapeutic gains with the use of traditional cytotoxic chemotherapy in advanced stage …

PARP inhibitors have transformed treatment for ovarian cancer, a cancer notable for
homologous recombination (HR) deficiencies and aberrant DNA repair, especially in the …

Clinical investigation of poly (ADP-ribose) polymerase (PARP) inhibitors for ovarian cancer
treatment has rapidly evolved from observations of single-agent in vitro activity of these …

High-grade serous ovarian cancer is characterized by genomic instability, with one half of all
tumors displaying defects in the important DNA repair pathway of homologous …

Ovarian cancer is the most lethal gynecologic malignancy with a high recurrence rate. Poly
(ADP-ribose) polymerase inhibitors (PARPi) are one of the most active new therapies for …

Inhibitors of poly (ADP-ribose) polymerase (PARP) are considered one of the most active
and exciting new therapies for the treatment of ovarian cancer. The anticancer activity of …

For several decades, the systemic treatment of ovarian cancer has involved chemotherapy,
with the relatively recent addition of antiangiogenic strategies given with chemotherapy and …

The standard of treatment for advanced ovarian cancer is represented by optimal surgical
debulking preceded or followed by chemotherapeutic regimens including taxanes and …

Purpose Ovarian cancer is the most lethal gynaecological malignancy. Despite the
introduction of bevacizumab, standard chemotherapy has remained largely unchanged and …

Ovarian cancer is the leading cause of gynecologic cancer death in women. Our
understanding of the treatment of ovarian cancer has evolved over the last decade, with the …